EyeGene initiates strategic RD overhaul with BMI Korea becoming largest shareholder - KBR

185490 Stock  KRW 2,825  5.00  0.18%   
About 62% of EyeGene's investor base is looking to short. The analysis of current outlook of investing in EyeGene suggests that many traders are alarmed regarding EyeGene's prospects. The current market sentiment, together with EyeGene's historical and current headlines, can help investors time the market. In addition, many technical investors use EyeGene stock news signals to limit their universe of possible portfolio assets.
  
EyeGene initiates strategic RD overhaul with BMI Korea becoming largest shareholder KBR

Read at news.google.com
Google News at Macroaxis
  

EyeGene Fundamental Analysis

We analyze EyeGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EyeGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EyeGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

EyeGene is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

EyeGene Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with EyeGene stock to make a market-neutral strategy. Peer analysis of EyeGene could also be used in its relative valuation, which is a method of valuing EyeGene by comparing valuation metrics with similar companies.

Complementary Tools for EyeGene Stock analysis

When running EyeGene's price analysis, check to measure EyeGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EyeGene is operating at the current time. Most of EyeGene's value examination focuses on studying past and present price action to predict the probability of EyeGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EyeGene's price. Additionally, you may evaluate how the addition of EyeGene to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Stocks Directory
Find actively traded stocks across global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges